Companies › Valent Technologies
1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| VAL-413 (Orotecan®) Topoisomerase I inhibitor | SN38 | Phase 1 | Solid Tumors | Dec 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT04337177 | VAL-413 (Orotecan®) | Phase 1 | Solid Tumors | Oncology | Dec 2026 |
–
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.